Sign in

CIK 0000949858

  • Non-accelerated filer
  • Smaller reporting company

ACHIEVE LIFE SCIENCES, INC.

Sign in to watch
Tickers
ACHV QUIT
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
954343413
Phone
+1 425-686-1500
Business address
22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
Former names
ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC

Securities

  • ACHV Common stock Nasdaq
  • QUIT Common Shares Nasdaq
  1. 4 Exercise or conversion EVP, CMO acquired 10,000 shares (option exercise)
  2. 4 Exercise or conversion President and CEO acquired 5,000 shares (option exercise)
  3. 4 Exercise or conversion Director acquired 3,347 shares (option exercise)
  4. 4 Exercise or conversion Principal Accounting Officer acquired 1,875 shares (option exercise)
  5. 4 Open-market sale President and CEO sold 10,000 shares at $16.52 ($165,200)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Exercise or conversion President and CEO acquired 5,000 shares (option exercise)
  11. 4 Open-market sale President and CEO sold 5,000 shares at $16.02 ($80,100)
  12. 4 Open-market sale President and CEO sold 5,000 shares at $15.99 ($79,950)
  13. 4 Open-market buy Principal Financial Officer bought 650 shares at $15.73 ($10,225)
  14. 4 Open-market sale President and CEO sold 5,000 shares at $15.45 ($77,250)
  15. 4 Exercise or conversion President & CEO acquired 1,761 shares (option exercise)
  16. 4 Derivatives Options or other derivatives
  17. 3 Insider Initial Statement of Ownership
  18. 4 Open-market sale Former Director sold 2,557 shares at $13.02 ($33,292)
  19. 4 Open-market sale Director sold 1,943 shares
  20. 4 Open-market sale Director sold 4,833 shares

Page 17 of 24 · 465 filings